Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bladder Cancer

  Free Subscription


Articles published in Eur Urol

Retrieve available abstracts of 196 articles:
HTML format



Single Articles


    October 2022
  1. MIRON B, Geynisman DM
    Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma.
    Eur Urol. 2022;82:374-376.
    PubMed    


  2. SIEFKER-RADTKE AO, Cho DC, Diab A, Sznol M, et al
    Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.
    Eur Urol. 2022;82:365-373.
    PubMed     Abstract available


    September 2022
  3. CATTO JWF, Khetrapal P, Ambler G, Williams NR, et al
    Reply to Bernardo Rocco and Maria Chiara Sighinolfi's Letter to the Editor re: James W.F. Catto, Pramit Khetrapal, Federico Ricciardi, et al. Effect of Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion vs Open Radical Cystectomy
    Eur Urol. 2022 Sep 13. pii: S0302-2838(22)02627.
    PubMed    


  4. KAVOUSSI M, Nasrallah AA, Williams SB
    Re: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guerin-naive High-risk Nonmuscle-invasive Bladder Cancer.
    Eur Urol. 2022 Sep 8. pii: S0302-2838(22)02615.
    PubMed    


  5. SUAREZ-CABRERA C, Estudillo L, Ramon-Gil E, Martinez-Fernandez M, et al
    BlaDimiR: A Urine-based miRNA Score for Accurate Bladder Cancer Diagnosis and Follow-up.
    Eur Urol. 2022 Sep 6. pii: S0302-2838(22)02562.
    PubMed    


  6. NAKAUMA-GONZALEZ JA, Rijnders M, van de Werken HJG, Lolkema MPJ, et al
    Reply to Yuxuan Song, Caipeng Qin, and Tao Xu's Letter to the Editor re: J. Alberto Nakauma-Gonzalez, Maud Rijnders, Job van Riet, et al. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Car
    Eur Urol. 2022;82:e78-e79.
    PubMed    


  7. SONG Y, Qin C, Xu T
    Re: J. Alberto Nakauma-Gonzalez, Maud Rijnders, Job van Riet, et al. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma. Eur Urol 2022;81:331-6: Novel Insights into Evidence of Metas
    Eur Urol. 2022;82:e76-e77.
    PubMed    


  8. GHATALIA P, Plimack ER
    Adding a Fourth Modality to Trimodal Therapy for Muscle-invasive Bladder Cancer.
    Eur Urol. 2022 Sep 1. pii: S0302-2838(22)02584.
    PubMed    


    August 2022
  9. MEGHANI K, Cooley LF, Choy B, Kocherginsky M, et al
    First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guerin.
    Eur Urol. 2022 Aug 22. pii: S0302-2838(22)02553.
    PubMed     Abstract available


  10. TAN WS, Prendergast A, Ackerman C, Yogeswaran Y, et al
    Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial.
    Eur Urol. 2022 Aug 20. pii: S0302-2838(22)02552.
    PubMed     Abstract available


  11. GIL-JIMENEZ A, van Dorp J, Contreras-Sanz A, van der Vos K, et al
    Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer.
    Eur Urol. 2022 Aug 11. pii: S0302-2838(22)02538.
    PubMed     Abstract available


  12. CARVALHO FLF, Mossanen M, Van Allen EM, Mouw KW, et al
    Reply to Yuxuan Song, Yiqing Du, and Tao Xu's Letter to the Editor re: Matthew Mossanen, Filipe L.F. Carvalho, Vinayak Muralidhar, et al. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol 2022;81:466-73.
    Eur Urol. 2022 Aug 6. pii: S0302-2838(22)02534.
    PubMed    


  13. CATTO JWF, Khetrapal P, Ambler G, Williams NR, et al
    Reply to Andreas Skolarikos's Words of Wisdom re: Effect of Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients with Bladder Cancer: A Randomized Clinical
    Eur Urol. 2022 Aug 6. pii: S0302-2838(22)02535.
    PubMed    


  14. SONG Y, Du Y, Xu T
    Re: Matthew Mossanena, Filipe L.F. Carvalhoa, Vinayak Muralidhar, et al. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol 2022;81:466-73.
    Eur Urol. 2022 Aug 5. pii: S0302-2838(22)02530.
    PubMed    


  15. SKOLARIKOS A
    Re: Effect of Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients with Bladder Cancer: A Randomized Clinical Trial.
    Eur Urol. 2022 Aug 3. pii: S0302-2838(22)02525.
    PubMed    


  16. DE RUITER BM, van Hattum JW, Lipman D, de Reijke TM, et al
    Phase 1 Study of Chemoradiotherapy Combined with Nivolumab +/- Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer.
    Eur Urol. 2022 Aug 3. pii: S0302-2838(22)02522.
    PubMed     Abstract available


  17. SZABADOS B, Kockx M, Assaf ZJ, van Dam PJ, et al
    Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
    Eur Urol. 2022;82:212-222.
    PubMed     Abstract available


  18. RAI BP, Luis Dominguez Escrig J, Vale L, Kuusk T, et al
    Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria.
    Eur Urol. 2022;82:182-192.
    PubMed     Abstract available


    July 2022
  19. TAKAHASHI T
    Re: Ekaterina Laukhtina, Shahrokh F. Shariat. Phase II Study of Gemcitabine and Split-dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.o
    Eur Urol. 2022 Jul 1. pii: S0302-2838(22)02466.
    PubMed    


  20. ADELEKE S, Tocco B, Kasivisvanathan V
    Re: Chemoradiotherapy in Muscle-invasive Bladder Cancer (BC2001): 10-year Follow-up of a Phase 3 Randomised Controlled Trial.
    Eur Urol. 2022 Jul 1. pii: S0302-2838(22)02470.
    PubMed    


    June 2022
  21. HANEY CM, Kriegmair MC, Michel MS, Stolzenburg JU, et al
    New Evidence and Innovative Approaches to Blinding in Robot-assisted Radical Cystectomy.
    Eur Urol. 2022;81:615-617.
    PubMed    


  22. PEEKER R
    Re: Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
    Eur Urol. 2022;81:619-620.
    PubMed    


    May 2022
  23. SOLANKI AA, Kates MR, Tran PT
    Paving the Road to the Future of Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-year Follow-up of BC2001.
    Eur Urol. 2022 May 28. pii: S0302-2838(22)02343.
    PubMed    


  24. RADZISZEWSKI P, Szablonski W
    Re: Bladder Cancer in Patients Younger than 40 Years: Outcomes from the National Cancer Database de la Calle CM, Washington SL 3rd, Lonergan PE, et al World J Urol 2021;39:1911-6.
    Eur Urol. 2022 May 19. pii: S0302-2838(22)01812.
    PubMed    


  25. HALL E, Hussain SA, Porta N, Lewis R, et al
    Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial.
    Eur Urol. 2022 May 13. pii: S0302-2838(22)02265.
    PubMed     Abstract available


  26. CONROY S, Nguyen AHT
    Compound to Clinic? A Preclinical High-throughput Screening Pathway To Expedite Drug Discovery in Bladder Cancer.
    Eur Urol. 2022 May 5. pii: S0302-2838(22)01811.
    PubMed    


  27. MCGREGOR B, O'Donnell PH, Balar A, Petrylak D, et al
    Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.
    Eur Urol. 2022;81:515-522.
    PubMed     Abstract available


  28. GEAVLETE P, Multescu R, Geavlete B
    Re: How to Manage Patients with Suspected Upper Tract Urothelial Carcinoma in the Pandemic of COVID-19?
    Eur Urol. 2022;81:543.
    PubMed    


  29. SJODAHL G, Abrahamsson J, Holmsten K, Bernardo C, et al
    Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
    Eur Urol. 2022;81:523-532.
    PubMed     Abstract available


    April 2022
  30. LAUKHTINA E, Shariat SF
    Re: Phase II Study of Gemcitabine and Split-dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer.
    Eur Urol. 2022 Apr 30. pii: S0302-2838(22)01816.
    PubMed    


  31. ERTL IE, Lemberger U, Ilijazi D, Hassler MR, et al
    Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound.
    Eur Urol. 2022 Apr 4. pii: S0302-2838(22)01678.
    PubMed     Abstract available


  32. GALLIOLI A, Breda A, Palou J
    Re: Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study.
    Eur Urol. 2022;81:428-429.
    PubMed    


  33. NAKAUMA-GONZALEZ JA, Rijnders M, van Riet J, van der Heijden MS, et al
    Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.
    Eur Urol. 2022;81:331-336.
    PubMed     Abstract available


    March 2022
  34. MAYR R, Eckstein M, Wirtz RM, Santiago-Walker A, et al
    Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guerin Immunotherapy.
    Eur Urol. 2022 Mar 26. pii: S0302-2838(22)01670.
    PubMed     Abstract available


  35. ALFRED WITJES J
    Re: Oncological Benefit of Re-resection for T1 Bladder Cancer: A Comparative Effectiveness Study.
    Eur Urol. 2022 Mar 25. pii: S0302-2838(22)01786.
    PubMed    


  36. WEINSTOCK C, Agrawal S, Chang E
    Optimizing Clinical Trial Design for Patients with Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2022 Mar 15. pii: S0302-2838(22)01655.
    PubMed    


  37. HENSLEY PJ, Kamat AM
    Re: Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
    Eur Urol. 2022;81:316-317.
    PubMed    


  38. CLEMENTS MB, Atkinson TM, Dalbagni GM, Li Y, et al
    Health-related Quality of Life for Patients Undergoing Radical Cystectomy: Results of a Large Prospective Cohort.
    Eur Urol. 2022;81:294-304.
    PubMed     Abstract available


    February 2022
  39. HUNG SF, Yii SC, Chung SD
    Re: Zhiwen Chen, Peng He, Xiaozhou Zhou, et al. Preliminary Functional Outcome Following Robotic Intracorporeal Orthotopic Ileal Neobladder Suspension with Round Ligaments in Women with Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eur
    Eur Urol. 2022 Feb 9. pii: S0302-2838(22)00077.
    PubMed    


  40. PARIKH DA, Khaki AR, Williams SB
    Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study.
    Eur Urol. 2022 Feb 4. pii: S0302-2838(22)00017.
    PubMed    


  41. HE P, Zhou X, Chen Z
    Reply to Shun-Fa Hung, Shyi-Chun Yii, and Shiu-Dong Chung's Letter to the Editor re: Zhiwen Chen, Peng He, Xiaozhou Zhou, et al. Preliminary Functional Outcome Following Robotic Intracorporeal Orthotopic Ileal Neobladder Suspension with Round Ligament
    Eur Urol. 2022 Feb 3. pii: S0302-2838(22)00081.
    PubMed    


  42. RUTKA JT, Fleshner N, Nathens AB
    Re: Jeremy Yuen-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Euro Urol 2021;80:442-9.
    Eur Urol. 2022;81:e51.
    PubMed    


    January 2022
  43. BRAUN A, Abbosh PH
    Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy: A Rare Entity with Unique Genomic Features.
    Eur Urol. 2022 Jan 30. pii: S0302-2838(22)00067.
    PubMed    


  44. BABJUK M
    Re: Long-term Experience with Radiofrequency-induced Hyperthermia Combined with Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer.
    Eur Urol. 2022 Jan 29. pii: S0302-2838(22)00023.
    PubMed    


  45. GROBET-JEANDIN E, Pinar U, Roupret M
    Re: Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study.
    Eur Urol. 2022 Jan 27. pii: S0302-2838(22)00012.
    PubMed    


  46. RENTSCH CA, Hayoz S, Cathomas RL
    Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicenter, Phase 2 Study.
    Eur Urol. 2022 Jan 24. pii: S0302-2838(22)00022.
    PubMed    


  47. SJODAHL G, Abrahamsson J, Holmsten K, Bernardo C, et al
    Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjodahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. In press. https://do
    Eur Urol. 2022 Jan 13. pii: S0302-2838(21)02284.
    PubMed    


  48. DE JONG JJ, Gibb EA
    Re: Gottfrid Sjodahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.10.035: Neoadjuvant Chemotherapy Resp
    Eur Urol. 2022 Jan 13. pii: S0302-2838(21)02281.
    PubMed    


  49. GROBET-JEANDIN E, Pinar U, Roupret M
    Re: Trey Durdin, Alvin Goh, Eugene Pietzak. Can an Imaging-guided Pathway Replace the Current Paradigm for Muscle-invasive Bladder Cancer? Eur Urol 2021;80:16-7: Transurethral Resection of Bladder Tumor in Diagnosis of Muscle-invasive Bladder Cancer:
    Eur Urol. 2022 Jan 11. pii: S0302-2838(21)02282.
    PubMed    


  50. CARMEN MIR M, Greenwell T, O'Kelly F, Proietti S, et al
    Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9. Eur Urol 2021;80
    Eur Urol. 2022;81:e26-e27.
    PubMed    


  51. CATHOMAS R, Lorch A, Bruins HM, Comperat EM, et al
    The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma.
    Eur Urol. 2022;81:95-103.
    PubMed     Abstract available


  52. SAAD S, Osman NI, Chapple CR
    Reply to Sanjay B. Kulkarni, Pankaj M. Joshi, Marco Bandini, et al.'s Letter to the Editor re: Sanad Saad, Nadir I. Osman, Christopher R. Chapple. Female Urethra: Is Ventral the True Dorsal? Eur Urol 2020;78:e218-9.
    Eur Urol. 2022;81:e16-e17.
    PubMed    


  53. LIEDBERG F, Abrahamsson J, Bobjer J
    Re: Keisuke Shigeta, Kazuhiro Matsumoto, Koichiro Ogihara, et al. Does Neoadjuvant Chemotherapy Have Therapeutic Benefit for Node-positive Upper Tract Urothelial Carcinoma? Results of a Multi-center Cohort Study. Urol Oncol. In press. https://doi.org/
    Eur Urol. 2022;81:e18-e19.
    PubMed    


  54. SHIGETA K, Matsumoto K, Oya M
    Reply to Fredrik Liedberg, Johan Abrahamsson, and Johannes Bobjer's Letter to the Editor re: Keisuke Shigeta, Kazuhiro Matsumoto, Koichiro Ogihara, et al. Does Neoadjuvant Chemotherapy have Therapeutic Benefit for Node-positive Upper Tract Urothelial
    Eur Urol. 2022;81:e20-e21.
    PubMed    


  55. DEV S
    Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9. Eur Urol 2021;80
    Eur Urol. 2022;81:e25.
    PubMed    


    December 2021
  56. ROUMIGUIE M, Kamat AM, Bivalacqua TJ, Lerner SP, et al
    International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guerin-exposed High-risk Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2021 Dec 23. pii: S0302-2838(21)02213.
    PubMed     Abstract available


  57. MOSSANEN M, Carvalho FLF, Muralidhar V, Preston MA, et al
    Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy.
    Eur Urol. 2021 Dec 22. pii: S0302-2838(21)02212.
    PubMed     Abstract available


  58. MITRA AP, Narayan VM, Mokkapati S, Miest T, et al
    Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial.
    Eur Urol. 2021 Dec 18. pii: S0302-2838(21)02217.
    PubMed     Abstract available


    November 2021
  59. CHEN Z, He P, Zhou X, Li P, et al
    Preliminary Functional Outcome Following Robotic Intracorporeal Orthotopic Ileal Neobladder Suspension with Round Ligaments in Women with Bladder Cancer.
    Eur Urol. 2021 Nov 30. pii: S0302-2838(21)02160.
    PubMed     Abstract available


  60. REIKE MJ, Adar R, Black PC
    Not "If", but "When" and "How": Testing Antibody-Drug Conjugates in Patients with Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2021 Nov 24. pii: S0302-2838(21)02151.
    PubMed    


  61. BURDETT S, Fisher DJ, Vale CL, Bono AV, et al
    Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials.
    Eur Urol. 2021 Nov 18. pii: S0302-2838(21)02058.
    PubMed     Abstract available


  62. ROBERTSON AG, Groeneveld CS, Jordan B, Lin X, et al
    Corrigendum to "Identification of Differential Tumor Subtypes of T1 Bladder Cancer" [Eur. Urol. 78 (2020) 533-537].
    Eur Urol. 2021 Nov 17. pii: S0302-2838(21)02143.
    PubMed    


  63. PATEL SR, Lerner SP
    Re: Identification of Differential Tumor Subtypes of T1 Bladder Cancer.
    Eur Urol. 2021 Nov 16. pii: S0302-2838(21)02119.
    PubMed    


  64. MIRON B, Bukavina L, Plimack ER
    Placing Adjuvant Chemotherapy in the Evolving Paradigm of Perioperative Therapy for Bladder Cancer.
    Eur Urol. 2021 Nov 5. pii: S0302-2838(21)02121.
    PubMed    


  65. CHOI W, Lombardo K, Patel S, Epstein G, et al
    A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-Guerin-exposed Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2021 Nov 1. pii: S0302-2838(21)02077.
    PubMed     Abstract available


    October 2021
  66. WOLDU SL, Lotan Y
    Re: ctDNA Guiding Adjuvant Immunotherapy in Urothelial Carcinoma.
    Eur Urol. 2021;80:517-518.
    PubMed    


  67. TEOH JY, Murphy DG, van Oort IM, Loeb S, et al
    Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yuen-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9.
    Eur Urol. 2021;80:e101.
    PubMed    


  68. FOERSTER B, Abufaraj M, Matin SF, Azizi M, et al
    Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study.
    Eur Urol. 2021;80:507-515.
    PubMed     Abstract available


    September 2021
  69. BABJUK M, Burger M, Capoun O, Cohen D, et al
    European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).
    Eur Urol. 2021 Sep 9. pii: S0302-2838(21)01978.
    PubMed     Abstract available


  70. CLINTON TN
    Defining Resistance to Immune Checkpoint Inhibitors in Urothelial Carcinoma: Insights from PURE-01.
    Eur Urol. 2021;80:323-324.
    PubMed    


    August 2021
  71. KARTOLO A, Kassouf W, Vera-Badillo FE
    Adjuvant Immune Checkpoint Inhibition in Muscle-invasive Bladder Cancer: Is It Ready for Prime Time?
    Eur Urol. 2021 Aug 5. pii: S0302-2838(21)01922.
    PubMed     Abstract available


  72. LI R, Jain RK, Sexton WJ
    Re: Andrea Necchi, Laura Marandino, Daniele Raggi, et al. Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer? Eur Urol 2021;79:713-6.
    Eur Urol. 2021 Aug 4. pii: S0302-2838(21)01925.
    PubMed    


  73. KESAVAN A, Esuvaranathan K
    Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study.
    Eur Urol. 2021 Aug 4. pii: S0302-2838(21)01923.
    PubMed    


  74. BEDKE J, Maas M
    Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
    Eur Urol. 2021;80:257-258.
    PubMed    


  75. MASSON-LECOMTE A, Meria P
    Re: Complications Associated with Ureteroscopic Management of Upper Tract Urothelial Carcinoma.
    Eur Urol. 2021;80:255.
    PubMed    


  76. SATISH P, Kuusk T, Campain N, Abu-Ghanem Y, et al
    The European Association of Urology COVID Intermediate-priority Group is Poorly Predictive of Pathological High Risk Among Patients with Renal Tumours.
    Eur Urol. 2021;80:265-267.
    PubMed    


  77. DELL'OGLIO P, Andras I, Ortega D, Galfano A, et al
    Impact of the Implementation of the EAU Guidelines Recommendation on Reporting and Grading of Complications in Patients Undergoing Robot-assisted Radical Cystectomy: A Systematic Review.
    Eur Urol. 2021;80:129-133.
    PubMed     Abstract available


    July 2021
  78. ALFRED WITJES J
    Re: Five-factor Prognostic Model for Survival of Post-platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
    Eur Urol. 2021;80:113.
    PubMed    


  79. VAN DER HEIJDEN MS, Loriot Y, Duran I, Ravaud A, et al
    Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial.
    Eur Urol. 2021;80:7-11.
    PubMed     Abstract available


  80. LI R, Gilbert SM, Kamat AM
    Unraveling the Mechanism of the Antitumor Activity of Bacillus Calmette-Guerin.
    Eur Urol. 2021;80:1-3.
    PubMed     Abstract available


    June 2021
  81. HU H
    Re: Richard T. Bryan, Wenyu Liu, Sarah J. Pirrie, et al. Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study. Eur Urol 2021;80:12-5.
    Eur Urol. 2021 Jun 29. pii: S0302-2838(21)01859.
    PubMed    


  82. KULKARNI GS
    Re: Radical Cystectomy Against Intravesical BCG for High-risk High-grade Nonmuscle Invasive Bladder Cancer: Results from the Randomized Controlled BRAVO-feasibility Study.
    Eur Urol. 2021 Jun 23. pii: S0302-2838(21)01803.
    PubMed    


  83. CIMADAMORE A, Lopez-Beltran A, Scarpelli M, Montironi R, et al
    Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. Eur Urol 2021;79:489-91.
    Eur Urol. 2021;79:e172-e173.
    PubMed    


  84. JONES TD, Cheng L
    Reply to Alessia Cimadamore, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Sys
    Eur Urol. 2021;79:e174-e175.
    PubMed    


    May 2021
  85. PEDERZOLI F, Bandini M, Raggi D, Marandino L, et al
    Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?
    Eur Urol. 2021 May 27. pii: S0302-2838(21)00387.
    PubMed     Abstract available


  86. HUSSAIN SA, Porta N, Hall E, Qureshi M, et al
    Reply to Santhanam Sundar and Paul Symonds' Letter to the Editor re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the
    Eur Urol. 2021 May 27. pii: S0302-2838(21)00347.
    PubMed    


  87. SUNDAR S, Symonds P
    Re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. Eur Urol 2021;79:307-15.
    Eur Urol. 2021 May 20. pii: S0302-2838(21)00345.
    PubMed    


  88. BRYAN RT, Catto JWF, Jefferson KP, Patel P, et al
    Reply to Trey Durdin, Alvin Goh, and Eugene Pietzak. Can an Imaging-guided Pathway Replace the Current Paradigm for Muscle-invasive Bladder Cancer? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.018.
    Eur Urol. 2021 May 7. pii: S0302-2838(21)00313.
    PubMed    


  89. PATEL SH, Kates M
    Open Versus Robot-assisted Radical Cystectomy: Is Standardization Without Randomization Possible?
    Eur Urol. 2021;79:619-620.
    PubMed    


  90. GAKIS G
    Re: Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
    Eur Urol. 2021;79:702.
    PubMed    


  91. LEOW JJ, Chong YL, Chang SL, Valderrama BP, et al
    Reply to Alexander Andreev-Drakhlin, Jianjun Gao, Arlene Siefker-Radtke. Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma. Eur Urol 2021;79:655-6.
    Eur Urol. 2021;79:657-658.
    PubMed    


  92. ANDREEV-DRAKHLIN A, Gao J, Siefker-Radtke A
    Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma.
    Eur Urol. 2021;79:655-656.
    PubMed    


  93. LEOW JJ, Chong YL, Chang SL, Valderrama BP, et al
    Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy.
    Eur Urol. 2021;79:635-654.
    PubMed     Abstract available


    April 2021
  94. DURDIN T, Goh A, Pietzak E
    Can an Imaging-guided Pathway Replace the Current Paradigm for Muscle-invasive Bladder Cancer?
    Eur Urol. 2021 Apr 8. pii: S0302-2838(21)00224.
    PubMed    


  95. ROUMIGUIE M, Contreras-Sanz A, Black PC
    Re: Ming Yuen Teo, Jose Mauricio Mota, Karissa A. Whiting, et al. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
    Eur Urol. 2021 Apr 7. pii: S0302-2838(21)00234.
    PubMed    


  96. PIAZZA P, Rosiello G, Chacon VT, Puliatti S, et al
    Robot-assisted Cystectomy with Intracorporeal Urinary Diversion After Pelvic Irradiation for Prostate Cancer: Technique and Results from a Single High-volume Center.
    Eur Urol. 2021 Apr 7. pii: S0302-2838(21)00229.
    PubMed     Abstract available


  97. JONES TD, Cheng L
    Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups.
    Eur Urol. 2021;79:489-491.
    PubMed    


  98. FUKUOKAYA W, Egawa S
    Re: Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab.
    Eur Urol. 2021;79:553-554.
    PubMed    


  99. XU P, Chen B, Xu A, Yuan D, et al
    Initial Experience with Intracorporeal Laparoscopic Radical Cystectomy and Detaenial Sigmoid Neobladder Reconstruction.
    Eur Urol. 2021;79:545-551.
    PubMed     Abstract available


    March 2021
  100. NECCHI A, de Jong JJ, Raggi D, Briganti A, et al
    Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab.
    Eur Urol. 2021 Mar 27. pii: S0302-2838(21)00212.
    PubMed     Abstract available


  101. GRIMM MO, Leucht K
    Re: Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
    Eur Urol. 2021;79:429-430.
    PubMed    


    February 2021
  102. BRYAN RT, Liu W, Pirrie SJ, Amir R, et al
    Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study.
    Eur Urol. 2021 Feb 27. pii: S0302-2838(21)00141.
    PubMed     Abstract available


  103. ROSIELLO G, Piazza P, Tames V, Farinha R, et al
    The Impact of Previous Prostate Surgery on Surgical Outcomes for Patients Treated with Robot-assisted Radical Cystectomy for Bladder Cancer.
    Eur Urol. 2021 Feb 27. pii: S0302-2838(21)00149.
    PubMed     Abstract available


  104. ABU-SALHA Y, Smith AB
    Seeing the Unseen: Uncovering Patient-reported Outcomes in Bladder Cancer.
    Eur Urol. 2021 Feb 23. pii: S0302-2838(21)00143.
    PubMed    


  105. GRABBERT M, Seiler R, Gratzke C
    Re: Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial Boorjian SA, Alemozaffar M, Konety BR, et al Lancet Oncol 2021;22:107-17.
    Eur Urol. 2021 Feb 20. pii: S0302-2838(21)00099.
    PubMed    


  106. SIGNORINI C, Maffezzini M
    Re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomized Controlled Trial. Eur Urol 2020;78:
    Eur Urol. 2021 Feb 13. pii: S0302-2838(21)00075.
    PubMed    


  107. LINDGREN MS, Jensen JB
    Reply to Claudia Signorini and Massimo Maffezzini's Letter to the Editor re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle
    Eur Urol. 2021 Feb 13. pii: S0302-2838(21)00085.
    PubMed    


  108. CATTO JWF, Downing A, Mason S, Wright P, et al
    Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes.
    Eur Urol. 2021 Feb 10. pii: S0302-2838(21)00073.
    PubMed     Abstract available


  109. SORIA F, Gontero P
    Re: Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial.
    Eur Urol. 2021 Feb 4. pii: S0302-2838(21)00066.
    PubMed    


  110. ALFRED WITJES J
    Re: Optimal Cystectomy Outcome: A Composite Measurement Evaluating Quality of Care and Mortality Benefit.
    Eur Urol. 2021;79:316.
    PubMed    


    January 2021
  111. LI R, Lerner SP, Kamat AM
    The Who, What, When, Where, and Why of Bacillus Calmette-Guerin-unresponsive Bladder Cancer.
    Eur Urol. 2021 Jan 13. pii: S0302-2838(21)00001.
    PubMed     Abstract available


  112. WIJBURG CJ, Michels CTJ, Grutters JPC, Rovers MM, et al
    Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Bladder Cancer Patients: A Multicentre Comparative Effectiveness Study.
    Eur Urol. 2021 Jan 11. pii: S0302-2838(20)31009.
    PubMed     Abstract available


  113. SYLVESTER RJ, Rodriguez O, Hernandez V, Turturica D, et al
    European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.
    Eur Urol. 2021 Jan 5. pii: S0302-2838(20)31019.
    PubMed     Abstract available


  114. PERERA-BEL J, Bellmunt J
    Reply to Anirban P. Mitra, Tanner Miest, and Colin P.N. Dinney's Words of Wisdom re: Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.euru
    Eur Urol. 2021 Jan 5. pii: S0302-2838(20)31024.
    PubMed    


  115. FODE M, Jensen CFS, Ostergren PB
    How Should the Medical Community Respond to the Low Quality of Medical Information on Social Media?
    Eur Urol. 2021;79:60-61.
    PubMed    


    December 2020
  116. GIANNARINI G, Valotto C, Ficarra V
    Re: Health Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial: A Multi-institutional Randomized Trial Comparing Robot Versus Open Radical Cystectomy.
    Eur Urol. 2020 Dec 19. pii: S0302-2838(20)30954.
    PubMed    


  117. POLETAJEW S, Krajewski W, Zdrojowy R, Kryst P, et al
    Re: Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.
    Eur Urol. 2020 Dec 10. pii: S0302-2838(20)30928.
    PubMed    


  118. HUSSAIN SA, Porta N, Hall E, Salawu A, et al
    Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial.
    Eur Urol. 2020 Dec 5. pii: S0302-2838(20)30937.
    PubMed     Abstract available


  119. DE VERE WHITE R, Dall'Era M
    Re: Quality Indicators for Bladder Cancer Services: A Collaborative Review.
    Eur Urol. 2020 Dec 5. pii: S0302-2838(20)30932.
    PubMed    


  120. MANTICA G, Terrone C, Der Merwe AV
    Bladder Cancer and Associated Risk Factors: The African Panorama.
    Eur Urol. 2020 Dec 3. pii: S0302-2838(20)30942.
    PubMed     Abstract available


    November 2020
  121. PANEBIANCO V, Del Giudice F, Narumi Y, Simone G, et al
    Re: Helena Vila-Reyes, G. Joel DeCastro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imag
    Eur Urol. 2020 Nov 28. pii: S0302-2838(20)30861.
    PubMed    


  122. VILA-REYES H, Joel DeCastro G, McKiernan JM
    Reply to Valeria Panebianco, Francesco Del Giudice, Yoshifumi Narumi, Giuseppe Simone, Ettore De Berardinis, and James Catto's Letter to the Editor re: Helena Vila-Reyes, G. Joel De Castro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai,
    Eur Urol. 2020 Nov 25. pii: S0302-2838(20)30883.
    PubMed    


  123. IYER G, Bochner BH, Van Allen EM, Solit DB, et al
    Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eu
    Eur Urol. 2020 Nov 17. pii: S0302-2838(20)30865.
    PubMed    


  124. BECKER REN, Baras A, Bivalacqua TJ
    Reply to Gopa Iyer, Bernard H. Bochner, Eliezer M. Van Allen, David B. Solit, and Jonathan E. Rosenberg's Letter to the Editor re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicato
    Eur Urol. 2020 Nov 17. pii: S0302-2838(20)30864.
    PubMed    


  125. BAKER SC, Mason AS, Southgate J
    Does a Novel Mutagenic Process Target KMT2D Mutation in the Most Common First Event on the Path to Bladder Cancer?
    Eur Urol. 2020 Nov 14. pii: S0302-2838(20)30866.
    PubMed    


  126. MITRA AP, Miest T, Dinney CPN
    Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer.
    Eur Urol. 2020 Nov 3. pii: S0302-2838(20)30809.
    PubMed    


    October 2020
  127. RIAZ IB, Hussain SA
    Perioperative Treatment in Muscle-invasive Bladder Cancer: Analysis of Secondary Endpoints in a Randomized Trial Comparing Gemcitabine and Cisplatin Versus Dose-dense Methotrexate, Vinblastine, Adriamycin, and Cisplatin.
    Eur Urol. 2020 Oct 1. pii: S0302-2838(20)30710.
    PubMed    


  128. SHAH A, Tan WP, Inman BA
    National Quality Improvement Program in Transurethral Resection of Bladder Tumor: A Model for the Rest of Us, Even if We Cannot Share All Results.
    Eur Urol. 2020;78:531-532.
    PubMed    


  129. GRIMBERG DC, Shah A, Inman BA
    En Bloc Resection of Bladder Tumors: Style or Substance?
    Eur Urol. 2020;78:570-571.
    PubMed    


    September 2020
  130. LOEB S, Reines K, Abu-Salha Y, French W, et al
    Quality of Bladder Cancer Information on YouTube.
    Eur Urol. 2020 Sep 30. pii: S0302-2838(20)30706.
    PubMed     Abstract available


  131. LIEDBERG F, Eriksson P, Sjodahl G
    Re: A. Gordon Robertson, Clarice S. Groeneveld, Brian Jordan, et al. Identification of Differential Tumor Subtypes of T1 Bladder Cancer. Eur Urol. In press. http://doi.org/10.1016/j.eururo.2020.06.048.
    Eur Urol. 2020 Sep 28. pii: S0302-2838(20)30708.
    PubMed    


  132. MEEKS JJ, Dyrsjkot L, Robertson AG
    Reply to Fredrik Liedberg, Pontus Eriksson, and Gottfrid Sjodahl's Letter to the Editor re: A. Gordon Robertson, Clarice S. Groeneveld, Brian Jordan, et al. Identification of Differential Tumor Subtypes of T1 Bladder Cancer. Eur Urol. In press. http:/
    Eur Urol. 2020 Sep 26. pii: S0302-2838(20)30722.
    PubMed    


  133. PACKIAM VT, Bhindi B
    Are We Moving Closer to Accurate Restaging after Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer?
    Eur Urol. 2020 Sep 23. pii: S0302-2838(20)30711.
    PubMed    


  134. TEOH JY, Huang J, Ko WY, Lok V, et al
    Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita.
    Eur Urol. 2020 Sep 21. pii: S0302-2838(20)30697.
    PubMed     Abstract available


    August 2020
  135. PANER GP, Montironi R
    Re: J. Alfred Witjes, Harman Max Bruins, Richard Cathomas, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.03
    Eur Urol. 2020 Aug 29. pii: S0302-2838(20)30631.
    PubMed    


  136. PFISTER C, Gravis G, Flechon A, Soulie M, et al
    Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Sec
    Eur Urol. 2020 Aug 28. pii: S0302-2838(20)30641.
    PubMed     Abstract available


  137. NECCHI A, Marandino L, Raggi D, Bandini M, et al
    Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer?
    Eur Urol. 2020 Aug 27. pii: S0302-2838(20)30639.
    PubMed     Abstract available


  138. FLIPPOT R, Loriot Y
    The FGFR3 Story in Bladder Cancer: Another Piece of the Puzzle?
    Eur Urol. 2020 Aug 24. pii: S0302-2838(20)30633.
    PubMed    


  139. VILA-REYES H, DeCastro GJ, McKiernan JM
    Re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscl
    Eur Urol. 2020 Aug 20. pii: S0302-2838(20)30623.
    PubMed    


  140. BALDAUF A, Koch R, Heberling U, Thomas C, et al
    Re: J. Alfred Witjes, Harman Max Bruins, Richard Cathomas, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.03
    Eur Urol. 2020 Aug 17. pii: S0302-2838(20)30617.
    PubMed    


  141. BECKER REN, Meyer AR, Brant A, Reese AC, et al
    Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
    Eur Urol. 2020 Aug 17. pii: S0302-2838(20)30564.
    PubMed     Abstract available


  142. MOSTAFID H
    Neoadjuvant Intravesical Therapy for Non-muscle-invasive Bladder Cancer: A New Approach for Old Agents?
    Eur Urol. 2020 Aug 9. pii: S0302-2838(20)30598.
    PubMed    


  143. WARD DG, Arnold R, Bryan RT
    Molecular Subtypes of T1 Bladder Cancer: Biomolecular Characteristics Versus Clinical Utility.
    Eur Urol. 2020 Aug 6. pii: S0302-2838(20)30569.
    PubMed    


  144. MONTORSI F, Bandini M, Necchi A
    Re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive
    Eur Urol. 2020;78:e75-e76.
    PubMed    


    July 2020
  145. MONTORSI F, Bandini M, Briganti A, Dasgupta P, et al
    Re-establishing the Role of Robot-assisted Radical Cystectomy After the 2020 EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel Recommendations.
    Eur Urol. 2020 Jul 28. pii: S0302-2838(20)30464.
    PubMed     Abstract available


  146. LINDGREN MS, Bue P, Azawi N, Blichert-Refsgaard L, et al
    The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomised Controlled Trial.
    Eur Urol. 2020 Jul 28. pii: S0302-2838(20)30541.
    PubMed     Abstract available


  147. WITJES JA, Ribal MJ, van der Heijden AG
    Reply to Francesco Montorsi, Marco Bandini, Alberto Briganti, et al. Re-establishing the Role of Robot-assisted Radical Cystectomy After the 2020 EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel Recommendations. Eur Urol. In press: Ca
    Eur Urol. 2020 Jul 18. pii: S0302-2838(20)30538.
    PubMed    


  148. MARIAPPAN P, Johnston A, Padovani L, Clark E, et al
    Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.
    Eur Urol. 2020 Jul 17. pii: S0302-2838(20)30511.
    PubMed     Abstract available


  149. ROBERTSON AG, Groeneveld CS, Jordan B, Lin X, et al
    Identification of Differential Tumor Subtypes of T1 Bladder Cancer.
    Eur Urol. 2020 Jul 16. pii: S0302-2838(20)30508.
    PubMed     Abstract available


  150. VAN RHIJN BWG, Mertens LS, Mayr R, Bostrom PJ, et al
    FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?(dagger).
    Eur Urol. 2020 Jul 15. pii: S0302-2838(20)30531.
    PubMed     Abstract available


  151. COMPERAT E
    Re: Greater Utility of Molecular Subtype Rather than Epithelial-to-mesenchymal Transition (EMT) Markers for Prognosis in High-risk Non-muscle-invasive (HGT1) Bladder Cancer.
    Eur Urol. 2020 Jul 3. pii: S0302-2838(20)30448.
    PubMed    


  152. WATERHOUSE JV, Hull JH, Linch M
    Corticosteroids for Urological Cancer Care During Coronavirus Disease 2019. Treat or Not to Treat?
    Eur Urol. 2020;78:9-10.
    PubMed     Abstract available


    June 2020
  153. MEEKS JJ, Robertson AG
    Immune Signatures Dominate Molecular Subtyping to Predict Response to Neoadjuvant Immunotherapy.
    Eur Urol. 2020;77:711-712.
    PubMed    


    May 2020
  154. WITJES JA, Babjuk M, Bellmunt J, Bruins HM, et al
    Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250
    Eur Urol. 2020 May 20. pii: S0302-2838(20)30192.
    PubMed    


  155. MARIAPPAN P
    Propensity for Quality: No Longer a Tenuous Proposition in Bladder Cancer.
    Eur Urol. 2020 May 19. pii: S0302-2838(20)30218.
    PubMed    


  156. VETTERLEIN MW, Gild P, Fisch M, Rink M, et al
    Reply to Francesco Montorsi, Marco Bandini, and Andrea Necchi's Letter to the Editor re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of U
    Eur Urol. 2020 May 3. pii: S0302-2838(20)30314.
    PubMed    


  157. BABJUK M
    Re: Multi-institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.
    Eur Urol. 2020 May 3. pii: S0302-2838(20)30252.
    PubMed    


  158. BABJUK M
    Are the Role of Surgery and its Complications Sufficiently Focused in the Era of Perioperative Systemic Treatments?
    Eur Urol. 2020;77:581-582.
    PubMed    


  159. MANTICA G, Terrone C
    Re: Eugene Shkolyar, Xiao Jia, Timothy C. Chang, et al. Augmented Bladder Tumor Detection Using Deep Learning. Eur Urol 2019;76:714-8.
    Eur Urol. 2020;77:e133.
    PubMed    


    April 2020
  160. WITJES JA, Bruins HM, Cathomas R, Comperat EM, et al
    European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.
    Eur Urol. 2020 Apr 29. pii: S0302-2838(20)30230.
    PubMed     Abstract available


  161. WOERL AC, Eckstein M, Geiger J, Wagner DC, et al
    Deep Learning Predicts Molecular Subtype of Muscle-invasive Bladder Cancer from Conventional Histopathological Slides.
    Eur Urol. 2020 Apr 27. pii: S0302-2838(20)30255.
    PubMed     Abstract available


  162. KAMAT AM
    Bladder Cancer Guidelines: Let Not the Cure Be Worse than the Disease.
    Eur Urol. 2020 Apr 27. pii: S0302-2838(20)30322.
    PubMed    


  163. PANEBIANCO V, Del Giudice F, Leonardo C, Sciarra A, et al
    VI-RADS Scoring Criteria for Alternative Risk-adapted Strategies in the Management of Bladder Cancer During the COVID-19 Pandemic.
    Eur Urol. 2020 Apr 27. pii: S0302-2838(20)30306.
    PubMed    


  164. LOUIS L, Thomas S, Yohann L, Morgan R, et al
    Adjustments in the Use of Intravesical Instillations of Bacillus Calmette-Guerin for High-risk Non-muscle-invasive Bladder Cancer During the COVID-19 Pandemic.
    Eur Urol. 2020 Apr 24. pii: S0302-2838(20)30302.
    PubMed     Abstract available


  165. SHAH A, Grimberg DC, Inman BA
    From Dog's Breakfast to Michelin Guide: Post-bacillus Calmette-Guerin Trials in Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2020 Apr 14. pii: S0302-2838(20)30197.
    PubMed    


    March 2020
  166. BAI Y, Yang Y, Tang Y
    Re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-0
    Eur Urol. 2020 Mar 18. pii: S0302-2838(20)30149.
    PubMed    


  167. NECCHI A, Gallina A, Dyrskjot L, Roupret M, et al
    Converging Roads to Early Bladder Cancer.
    Eur Urol. 2020 Mar 17. pii: S0302-2838(20)30141.
    PubMed    


  168. MOSTAFID H, Babjuk M, Bochner B, Lerner SP, et al
    Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer.
    Eur Urol. 2020 Mar 16. pii: S0302-2838(20)30146.
    PubMed     Abstract available


  169. BANDINI M, Necchi A
    Reply to Yunjin Bai, Yubo Yang, Yin Tang's Letter to the Editor, re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Mus
    Eur Urol. 2020 Mar 14. pii: S0302-2838(20)30150.
    PubMed    


  170. HUDDART R, Hall E, Lewis R, Porta N, et al
    Reply to Wei Liu, Xiaoping Liu, Sheng Li's Letter to the Editor, re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy +/- Chemotherap
    Eur Urol. 2020 Mar 10. pii: S0302-2838(20)30119.
    PubMed    


  171. NECCHI A, Raggi D, Gallina A, Ross JS, et al
    Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
    Eur Urol. 2020 Mar 9. pii: S0302-2838(20)30138.
    PubMed     Abstract available


  172. LI R, Sundi D, Zhang J, Kim Y, et al
    Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guerin.
    Eur Urol. 2020 Mar 3. pii: S0302-2838(20)30118.
    PubMed     Abstract available


    February 2020
  173. LIU W, Liu X, Li S
    Re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy +/- Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. Eur Urol.
    Eur Urol. 2020 Feb 26. pii: S0302-2838(20)30120.
    PubMed    


  174. KAMOUN A, de Reynies A, Allory Y, Sjodahl G, et al
    Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol. In press.
    Eur Urol. 2020 Feb 6. pii: S0302-2838(19)30958.
    PubMed    


    January 2020
  175. DEL GIUDICE F, Catto JWF, Panebianco V
    Reply to Charalampos Fragkoulis, Georgios Papadopoulos, and Konstantinos Ntoumas's Letter to the Editor re: Francesco Del Giudice, Giovanni Barchetti, Ettore De Berardinis, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI
    Eur Urol. 2020 Jan 28. pii: S0302-2838(20)30056.
    PubMed    


  176. FRAGKOULIS C, Papadopoulos G, Ntoumas K
    Re: Francesco Del Giudice, Giovanni Barchetti, Ettore De Berardinis, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patient
    Eur Urol. 2020 Jan 21. pii: S0302-2838(20)30053.
    PubMed    


  177. BRIGANTI A, Gandaglia G, Scuderi S, Gallina A, et al
    Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial.
    Eur Urol. 2020 Jan 3. pii: S0302-2838(19)30963.
    PubMed     Abstract available


  178. MCGRATH JS, Smith AB, Williams SB
    The Complexity of Complications: How Do We Estimate Morbidity and Target Improvements Following Radical Cystectomy?
    Eur Urol. 2020;77:66-67.
    PubMed    


  179. VETTERLEIN MW, Rink M
    Reply to Liang Sun and Yi Feng's Letter to the Editor re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Sta
    Eur Urol. 2020;77:e12-e13.
    PubMed    


  180. SUN L, Feng Y
    Re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive
    Eur Urol. 2020;77:e10-e11.
    PubMed    


  181. KHAN MS, Omar K, Ahmed K, Gan C, et al
    Long-term Oncological Outcomes from an Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL).
    Eur Urol. 2020;77:110-118.
    PubMed     Abstract available


  182. MOSCHINI M, Shariat SF, Black P, Kamat AM, et al
    Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails.
    Eur Urol. 2020;77:1-2.
    PubMed     Abstract available


  183. VETTERLEIN MW, Klemm J, Gild P, Bradtke M, et al
    Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index.
    Eur Urol. 2020;77:55-65.
    PubMed     Abstract available


    December 2019
  184. NECCHI A, Bandini M, Calareso G, Raggi D, et al
    Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study.
    Eur Urol. 2019 Dec 24. pii: S0302-2838(19)30960.
    PubMed     Abstract available


  185. HUDDART RA, Hall E, Lewis R, Porta N, et al
    Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy +/- Chemotherapy in the BC2001 Phase III Randomised Controlled Trial.
    Eur Urol. 2019 Dec 13. pii: S0302-2838(19)30840.
    PubMed     Abstract available


  186. THIBAULT C, Lavaud P, Loriot Y
    Studying Rarity in Bladder Cancer.
    Eur Urol. 2019 Dec 4. pii: S0302-2838(19)30891.
    PubMed    


    November 2019
  187. WILLIAMS SB, Black PC, Dyrskjot L, Seiler R, et al
    Re: Aurelie Kamoun, Aurelien de Reynies, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.09.006: A Statement from the International Bladder Cancer Ne
    Eur Urol. 2019 Nov 28. pii: S0302-2838(19)30874.
    PubMed    


  188. WITJES JA, Babjuk M, Bellmunt J, Bruins HM, et al
    EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort(dagger): Under the Auspices of the EAU-ESMO Guidelines Committees.
    Eur Urol. 2019 Nov 16. pii: S0302-2838(19)30763.
    PubMed     Abstract available


  189. DEL GIUDICE F, Barchetti G, De Berardinis E, Pecoraro M, et al
    Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
    Eur Urol. 2019 Nov 4. pii: S0302-2838(19)30757.
    PubMed     Abstract available


    October 2019
  190. YATAI KB, Tran H, Dunning MJ, Wang D, et al
    Sources of Bias Within Consensus Subtypes of Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Oct 23. pii: S0302-2838(19)30760.
    PubMed    


    September 2019
  191. KETTUNEN K, Bostrom P, Taimen P
    Reply to Xuefeng Liu's Letter to the Editor, re: Kimmo Kettunen, Peter J. Bostrom, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol. In press. https://do
    Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30731.
    PubMed    


  192. LIU X
    Re: Kimmo Kettunen, Peter J. Bostrom, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.06.016: Can Patie
    Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30734.
    PubMed    


  193. KRIEGMAIR MC, Rother J, Grychtol B, Theuring M, et al
    Multiparametric Cystoscopy for Detection of Bladder Cancer Using Real-time Multispectral Imaging.
    Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30674.
    PubMed     Abstract available


  194. KAMOUN A, Reynies A, Allory Y, Sjodahl G, et al
    A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Sep 25. pii: S0302-2838(19)30695.
    PubMed     Abstract available


  195. LEOW JJ, Catto JWF, Efstathiou JA, Gore JL, et al
    Quality Indicators for Bladder Cancer Services: A Collaborative Review.
    Eur Urol. 2019 Sep 25. pii: S0302-2838(19)30690.
    PubMed     Abstract available


    May 2019
  196. SUNDAHL N, Vandekerkhove G, Decaestecker K, Meireson A, et al
    Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma.
    Eur Urol. 2019;75:707-711.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: